These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17482393)

  • 1. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant.
    Iyer SS; Barr WH; Dance ME; Coleman PR; Karnes HT
    Int J Pharm; 2007 Aug; 340(1-2):104-18. PubMed ID: 17482393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant.
    Iyer SS; Barr WH; Karnes HT
    Int J Pharm; 2007 Aug; 340(1-2):119-25. PubMed ID: 17482777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a potential medium for 'biorelevant' in vitro release testing of a naltrexone implant, employing a validated stability-indicating HPLC method.
    Iyer SS; Barr WH; Karnes HT
    J Pharm Biomed Anal; 2007 Feb; 43(3):845-53. PubMed ID: 17045445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biorelevant in vitro release/permeation system for oral transmucosal dosage forms.
    Delvadia PR; Barr WH; Karnes HT
    Int J Pharm; 2012 Jul; 430(1-2):104-13. PubMed ID: 22486954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The solubility and in vivo-in vitro correlation of naltrexone].
    Navarro Guerrero J; Ruiz Ramirez JC; Lorduy Oses L
    Boll Chim Farm; 1998 Jan; 137(1):16-20. PubMed ID: 9595829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of parenteral sustained-release naltrexone systems.
    Olsen JL; Kincl FA
    NIDA Res Monogr; 1981; 28():187-93. PubMed ID: 6791004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development.
    Iyer SS; Barr WH; Karnes HT
    Biopharm Drug Dispos; 2006 May; 27(4):157-70. PubMed ID: 16416503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs.
    Campisi G; Giannola LI; Florena AM; De Caro V; Schumacher A; Göttsche T; Paderni C; Wolff A
    J Control Release; 2010 Aug; 145(3):214-20. PubMed ID: 20438777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants.
    Li C; Cheng L; Zhang Y; Guo S; Wu W
    Int J Pharm; 2010 Feb; 386(1-2):23-9. PubMed ID: 19895876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH; Malspeis L; Frank S; Notari RE
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):43-5. PubMed ID: 823438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic quantitation of naltrexone release from several sustained-release delivery systems.
    Reuning RH; Liao SH; Staubus AE
    NIDA Res Monogr; 1981; 28():172-84. PubMed ID: 6791003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres.
    Andhariya JV; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
    J Control Release; 2017 Jun; 255():27-35. PubMed ID: 28385676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
    Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
    J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design.
    Giannola LI; De Caro V; Giandalia G; Siragusa MG; Tripodo C; Florena AM; Campisi G
    Eur J Pharm Biopharm; 2007 Sep; 67(2):425-33. PubMed ID: 17451927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma.
    Clavijo C; Bendrick-Peart J; Zhang YL; Johnson G; Gasparic A; Christians U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):33-41. PubMed ID: 18805072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of matrix controlled transdermal delivery systems of pentazocine: In vitro/in vivo performance.
    Prasad Verma PR; Chandak AR
    Acta Pharm; 2009 Jun; 59(2):171-86. PubMed ID: 19564142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood naltrexone levels over time following naltrexone implant.
    Ngo HT; Arnold-Reed DE; Hansson RC; Tait RJ; Hulse GK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):23-8. PubMed ID: 17651881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel application of the T-cell for flow-through dissolution: the case of bioceramics used as ibuprofen carrier.
    Chevalier E; Viana M; Artaud A; Haddouchi S; Chulia D
    Talanta; 2009 Feb; 77(4):1545-8. PubMed ID: 19084677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.